Abstract. Early (20 min) thyroid radio-iodine uptake (ERU) and thyroid-stimulating antibodies (TSab) were determined in 27 untreated unselected patients with Graves' disease at the time of diagnosis. In 21 subjects the same tests were further performed in parallel during combined carbimazole-L-T3 therapy (mean duration of follow-up: 10.8 \ m=+-\5.8 months; mean \ m=+-\sd). TSab was determined by a cAMP-human thyrocyte culture stimulation assay and expressed in \g=m\l-equivalent of a TSab standard/ml (\g=m\l-eq/ml). Before treatment, ERU, ranging from 15 to 54% of the injected dose (normal \ m=l e\ 8% dose) correlated with serum T3 (r: 0.54; P < 0.01);
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TSab, ranging from 6 to 85 \g=m\l-eq/ml was detected in 21/27 patients. There was a significant correlation between ERU and TSab (Spearman rank test: r: 0.57; P < 0.01). During the first months of treatment, 5 of the 21 patients sequentially studied had undetectable TSab levels throughout the study and in these patients ERU decreased by 57% of its initial value; the remaining 16 subjects were divided into two groups according to ERU changes: in group A (9 patients), initial ERU decreased by 50% or more or the absolute value became less than 20% of the dose and TSab decreased from 10.9 \m=+-\4.8 ** to 5.3 \m=+-\1.6 \g=m\l-eq/ml (P < 0.01); in group B (7 patients), the fall of ERU was less than 50% or the absolute value remained greater than 20% of the dose and TSab values remained unchanged. Furthermore Thyroid-stimulating immunoglobulins are in¬ volved in the pathogenesis of Graves' disease. Evaluation of the relationship between circulating TSab levels and the degree of thyroid hyperfunction has practical as well as pathophysiological importance. Thyroid uptake, determined early after radio-iodine injection, measures the iodide trapping mechanism which closely reflects thyroid activity (Higgins 1955 ERU and TSab values before treatment (I) and at 3 -7 months of follow-up under therapy (T) in patients in whom (panel a) ERU decreased by 50% or more of its inital value or the absolute value became less than 20% of the dose (group A, = 9) or ERU fell by less than 50% or the absolute value remained greater than 20% of the dose (group , = 7), and (panel b) patients in whom TSab were initially undetectable.
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The relationship between ERU and TSab was evaluated during the first months of carbimazole-L-T3 treatment. Since the purpose of this study was to compare changes in ERU and TSab levels, the 5 patients in whom TSab remained undetectable throughout the study were considered as a separate group (Fig. 2, panel 
